Skip Navigation
Toggle Menu
News & Events
Careers
Contact
About us
Background
History
Vision & Mission
Board of Directors
Suven Neuro
Locations
Business Segments
Drug Discovery & Development Support Services (DDDSS)
Synthetic and Medicinal Chemistry
Analytical Chemistry
In vitro Biology
ADME
Pharmacology
Toxicology
Bioanalysis
NCE Formulations
Drug Discovery & Research/Clinical pipeline
Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's
Masupirdine (SUVN-502) Cognitive deficits in AD
Samelisant (SUVN-G3031) Narcolepsy
Samelisant (SUVN-G3031) Cognitive Disorders
Ropanicant (SUVN-911) Depressive Disorders
Usmarapride (SUVN-D4010), Cognitive Disorders
SUVN-I6107, Cognitive Disorders and Schizophrenia
SUVN-M8036, Psychiatric Disorders
SUVN-D1044 Gastrointestinal Disorders
Clinical Pipeline
Research Pipeline
Investors
Financial Info
Quarterly Release
Annual Reports
Subsidiary Accounts
Pharma Results
Share Holder’s Info
Statutory Communications
Stock Information
AGM
EGM
Postal Ballot
Notice of Board Meeting
Un-paid Dividends
Scheme of Arrangement
Others
Rights Issue 2022
Corporate Info
Presentations
Advertisements
Credit Rating
Business Segments
Share Holder Contacts
Registrar & Share Transfer Agents (RTA)
Patent Updates
Corporate Governance
Committees of Board
Directors Familiarization program
Terms and conditions of appointment of ID’s
Policies
Code of Conduct
Sustainability
IMS Policy
Certifications & Awards
CSR Policies
CSR Gallery
BRSR Policies
Search
Quarterly Release
Home
Investors
Financial Info
Quarterly Release
FY 2012-2013
Quarter 1
Results
Press Release
Investor Communication
Quarter 2
Results
Press Release
Investor Communication
Quarter 3
Results
Press Release
Investor Communication
Quarter 4
Results
Press Release
Investor Communication
FY 2010-2011
Quarter 1
Quarter 2
Results
Press Release
Investor Communication
Quarter 3
Results
Press Release
Investor Communication
Quarter 4
Results
Press Release
Investor Communication
BACK